Positive results from completed Phase 2 study of mavorixafor in chronic neutropenia (CN) announced todayPivotal Phase 3 trial of mavorixafor in ...

There is no shortage of ASX healthcare companies with upcoming catalysts – a focal point for investors. ... Read More The ...

The FDA said it was “unable to approve the supplemental new drug application (sNDA ... The EC made its decision following the ...

Target patient enrollment of 92 evaluable patients achieved in the VIRAGE Phase 2b clinical trial of VCN-01 in patients with metastatic ...

As of Oct. 31, Zevra has received 90 prescription enrollment forms for MIPLYFFA of which 30% are approved ... MIPLYFFA was further granted Orphan Medicinal Product designation by the European ...

submission to the FDA and a Marketing Authorization Application (MAA) submission to the European Medicines Agency (EMA) in 2026, assuming positive study results. Additionally, Quince was granted Fast ...

Net cash used in operating and investing activities was $45.2 million and $102.5 million for the third quarter and first nine months of 2024, respectively; quarter-end cash and restricted cash positio ...

OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and nine months ended September 30, 2024, and provided operating and partner program ...

The EU Commission had issued an extension to manufacturers to sign up with a notified body for EU Medical Devices Regulation ...

There, you need to fill up and submit the application form provided by the officials after paying Rs.25 plus GST. you must fill out and submit the application form that has been issued by the staff ...

All times are UK and subject to change. BBC is not responsible for any changes. © 2024 BBC. The BBC is not responsible for the content of external sites. Read about ...

The Official Journal of the European Union is the official publication (gazette) for EU legal acts, other acts and official information from EU institutions, bodies, offices and agencies. It is ...